Top Markets
Coin of the day
Grace Therapeutics, Inc. Grace Therapeutics, Inc.

Grace Therapeutics, Inc.

GRCE
Rangering i aksjer #27036
Grace Therapeutics, Inc. specializes in the creation and commercialization of... Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Aksjekurs
$2.18
Sist synkronisert: 2026-08-19
Markedsverdi
$35.55M
Endring (1 dag)
2.57%
Endring (1 år)
-33.19%
Land
US
Handel Grace Therapeutics, Inc. (GRCE)

Kategori

Utbytteavkastning for Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (aksjesymbol: GRCE) sin utbytteavkastning (TTM) per 2026 er: 0
Gjennomsnittlig utbytteavkastning de siste 5 årene: 0.00%
Utbytteavkastning for Grace Therapeutics, Inc. (GRCE) fra 2026 til 2026
Utbytteavkastning ved slutten av hvert år (TTM)
År Utbytteavkastning Endre
Ikke nok data for de angitte datoene.
Utbytteavkastning (TTM) for lignende selskaper eller konkurrenter
Selskap Utbytteavkastning Land
0.00%
US
0.00%
US
0.00%
NL
3.12%
AU
0.00%
CH